Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

Outcomes of secondary cytoreductive surgery for patients with platinum-sensitive recurrent ovarian cancer.

Gockley A, Melamed A, Cronin A, Bookman MA, Burger RA, Cristae MC, Griggs JJ, Mantia-Smaldone G, Matulonis UA, Meyer LA, Niland J, O'Malley DM, Wright AA.

Am J Obstet Gynecol. 2019 Jun 14. pii: S0002-9378(19)30773-2. doi: 10.1016/j.ajog.2019.06.009. [Epub ahead of print]

PMID:
31207237
2.

A phase 1b dose escalation study of ipafricept (OMP54F28) in combination with paclitaxel and carboplatin in patients with recurrent platinum-sensitive ovarian cancer.

Moore KN, Gunderson CC, Sabbatini P, McMeekin DS, Mantia-Smaldone G, Burger RA, Morgan MA, Kapoun AM, Brachmann RK, Stagg R, Farooki A, O'Cearbhaill RE.

Gynecol Oncol. 2019 Aug;154(2):294-301. doi: 10.1016/j.ygyno.2019.04.001. Epub 2019 Jun 4.

PMID:
31174889
3.

A preoperative risk score to predict red blood cell transfusion in patients undergoing hysterectomy for ovarian cancer.

Ackroyd SA, Brown J, Houck K, Chu C, Mantia-Smaldone G, Rubin S, Hernandez E.

Am J Obstet Gynecol. 2018 Dec;219(6):598.e1-598.e10. doi: 10.1016/j.ajog.2018.09.011. Epub 2018 Sep 18.

PMID:
30240655
4.

National Cancer Database Report of Lymphadenectomy Trends in Endometrial Cancer.

Cripe J, Handorf E, Brown J, Jain A, Rubin S, Mantia-Smaldone G.

Int J Gynecol Cancer. 2017 Sep;27(7):1408-1415. doi: 10.1097/IGC.0000000000001005.

PMID:
28525495
5.

Active Estrogen Receptor-alpha Signaling in Ovarian Cancer Models and Clinical Specimens.

Andersen CL, Sikora MJ, Boisen MM, Ma T, Christie A, Tseng G, Park Y, Luthra S, Chandran U, Haluska P, Mantia-Smaldone GM, Odunsi K, McLean K, Lee AV, Elishaev E, Edwards RP, Oesterreich S.

Clin Cancer Res. 2017 Jul 15;23(14):3802-3812. doi: 10.1158/1078-0432.CCR-16-1501. Epub 2017 Jan 10.

6.

Use and Effectiveness of Neoadjuvant Chemotherapy for Treatment of Ovarian Cancer.

Meyer LA, Cronin AM, Sun CC, Bixel K, Bookman MA, Cristea MC, Griggs JJ, Levenback CF, Burger RA, Mantia-Smaldone G, Matulonis UA, Niland JC, O'Malley DM, Wright AA.

J Clin Oncol. 2016 Nov 10;34(32):3854-3863. doi: 10.1200/JCO.2016.68.1239.

7.

Use of CA-125 Tests and Computed Tomographic Scans for Surveillance in Ovarian Cancer.

Esselen KM, Cronin AM, Bixel K, Bookman MA, Burger RA, Cohn DE, Cristea M, Griggs JJ, Levenback CF, Mantia-Smaldone G, Meyer LA, Matulonis UA, Niland JC, Sun C, O'Malley DM, Wright AA.

JAMA Oncol. 2016 Nov 1;2(11):1427-1433. doi: 10.1001/jamaoncol.2016.1842.

8.

The role of adjuvant radiation in lymph node positive endometrial adenocarcinoma.

Shaikh T, Churilla TM, Mantia-Smaldone GM, Chu C, Rubin SC, Anderson PR.

Gynecol Oncol. 2016 Jun;141(3):434-439. doi: 10.1016/j.ygyno.2016.04.010. Epub 2016 Apr 21.

PMID:
27090796
9.

Disparities in the management and outcome of cervical cancer in the United States according to health insurance status.

Churilla T, Egleston B, Dong Y, Shaikh T, Murphy C, Mantia-Smaldone G, Chu C, Rubin S, Anderson P.

Gynecol Oncol. 2016 Jun;141(3):516-523. doi: 10.1016/j.ygyno.2016.03.025. Epub 2016 Mar 25.

10.

Genetic testing for hereditary cancer predisposition: BRCA1/2, Lynch syndrome, and beyond.

Hall MJ, Obeid EI, Schwartz SC, Mantia-Smaldone G, Forman AD, Daly MB.

Gynecol Oncol. 2016 Mar;140(3):565-74. doi: 10.1016/j.ygyno.2016.01.019. Epub 2016 Jan 23. Review.

11.

Use and Effectiveness of Intraperitoneal Chemotherapy for Treatment of Ovarian Cancer.

Wright AA, Cronin A, Milne DE, Bookman MA, Burger RA, Cohn DE, Cristea MC, Griggs JJ, Keating NL, Levenback CF, Mantia-Smaldone G, Matulonis UA, Meyer LA, Niland JC, Weeks JC, O'Malley DM.

J Clin Oncol. 2015 Sep 10;33(26):2841-7. doi: 10.1200/JCO.2015.61.4776. Epub 2015 Aug 3.

12.

CTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer.

Higuchi T, Flies DB, Marjon NA, Mantia-Smaldone G, Ronner L, Gimotty PA, Adams SF.

Cancer Immunol Res. 2015 Nov;3(11):1257-68. doi: 10.1158/2326-6066.CIR-15-0044. Epub 2015 Jul 2.

13.

Complement pathway is frequently altered in endometriosis and endometriosis-associated ovarian cancer.

Suryawanshi S, Huang X, Elishaev E, Budiu RA, Zhang L, Kim S, Donnellan N, Mantia-Smaldone G, Ma T, Tseng G, Lee T, Mansuria S, Edwards RP, Vlad AM.

Clin Cancer Res. 2014 Dec 1;20(23):6163-74. doi: 10.1158/1078-0432.CCR-14-1338. Epub 2014 Oct 7.

14.

Surgical diagnosis of stage I fallopian tube cancer in anti-Yo antibody paraneoplastic cerebellar degeneration.

Haggerty AF, Mantia-Smaldone G, Siegelman E, Livolsi V, Tanyi J.

J Obstet Gynaecol. 2015 Jan;35(1):100-1. doi: 10.3109/01443615.2014.930095. Epub 2014 Jun 24. No abstract available.

PMID:
24960213
15.

The immunomodulatory effects of pegylated liposomal doxorubicin are amplified in BRCA1--deficient ovarian tumors and can be exploited to improve treatment response in a mouse model.

Mantia-Smaldone G, Ronner L, Blair A, Gamerman V, Morse C, Orsulic S, Rubin S, Gimotty P, Adams S.

Gynecol Oncol. 2014 Jun;133(3):584-90. doi: 10.1016/j.ygyno.2014.03.565. Epub 2014 Mar 27.

PMID:
24680909
16.

Vertebral artery dissection and cerebral infarction in a patient with recurrent ovarian cancer receiving bevacizumab.

Mantia-Smaldone GM, Bagley LJ, Kasner SE, Chu CS.

Gynecol Oncol Case Rep. 2013 Apr 11;5:37-9. doi: 10.1016/j.gynor.2013.04.002. eCollection 2013.

17.

Metastatic cholangiocarcinoma to the ovary: a case series.

Corr BR, Mantia-Smaldone G, Cantor J, Livolsi VA, Furth E, Chu CS.

Int J Gynecol Pathol. 2013 Nov;32(6):562-5. doi: 10.1097/PGP.0b013e3182782b9f.

PMID:
24071872
18.

A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedside.

Chiang CL, Kandalaft LE, Tanyi J, Hagemann AR, Motz GT, Svoronos N, Montone K, Mantia-Smaldone GM, Smith L, Nisenbaum HL, Levine BL, Kalos M, Czerniecki BJ, Torigian DA, Powell DJ Jr, Mick R, Coukos G.

Clin Cancer Res. 2013 Sep 1;19(17):4801-15. doi: 10.1158/1078-0432.CCR-13-1185. Epub 2013 Jul 9.

19.

A review of dendritic cell therapy for cancer: progress and challenges.

Mantia-Smaldone GM, Chu CS.

BioDrugs. 2013 Oct;27(5):453-68. doi: 10.1007/s40259-013-0030-9. Review.

PMID:
23592406
20.

Plasma microRNAs as novel biomarkers for endometriosis and endometriosis-associated ovarian cancer.

Suryawanshi S, Vlad AM, Lin HM, Mantia-Smaldone G, Laskey R, Lee M, Lin Y, Donnellan N, Klein-Patel M, Lee T, Mansuria S, Elishaev E, Budiu R, Edwards RP, Huang X.

Clin Cancer Res. 2013 Mar 1;19(5):1213-24. doi: 10.1158/1078-0432.CCR-12-2726. Epub 2013 Jan 29.

21.

Immunotherapy in ovarian cancer.

Mantia-Smaldone GM, Corr B, Chu CS.

Hum Vaccin Immunother. 2012 Sep;8(9):1179-91. doi: 10.4161/hv.20738. Epub 2012 Aug 21. Review.

22.

Targeted treatment of recurrent platinum-resistant ovarian cancer: current and emerging therapies.

Mantia-Smaldone GM, Edwards RP, Vlad AM.

Cancer Manag Res. 2011;3:25-38. doi: 10.2147/CMR.S8759. Epub 2010 Dec 30.

23.

Soluble MUC1 and serum MUC1-specific antibodies are potential prognostic biomarkers for platinum-resistant ovarian cancer.

Budiu RA, Mantia-Smaldone G, Elishaev E, Chu T, Thaller J, McCabe K, Lenzner D, Edwards RP, Vlad AM.

Cancer Immunol Immunother. 2011 Jul;60(7):975-84. doi: 10.1007/s00262-011-1010-x. Epub 2011 Apr 2.

PMID:
21461842
24.

Conservative management of postoperatively diagnosed cystotomy.

Alperin M, Mantia-Smaldone G, Sagan ER.

Urology. 2009 May;73(5):1163.e17-9. doi: 10.1016/j.urology.2008.03.047. Epub 2008 Jun 2.

PMID:
18514295

Supplemental Content

Loading ...
Support Center